Evidence map›Paper›PMID 42889618›Full record

ArticleACS omega2026

Repurposing of Milciclib as a Potential Inhibitor of

Rafael Martins de Oliveira, Natália Carine Lima Dos Santos, Joed Pires de Lima Júnior, Luana Carvalho Luz, Marcos Paulo Oliveira Almeida, Guilherme de Souza, Izadora Santos Damasceno, Muriel Pereira Souto, Rosiane Nascimento Alves, Angelica Oliveira Gomes and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rafael Martins de OliveiraLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Natália Carine Lima Dos SantosLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Joed Pires de Lima JúniorLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Luana Carvalho LuzLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Marcos Paulo Oliveira AlmeidaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Guilherme de SouzaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Izadora Santos DamascenoLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Muriel Pereira SoutoLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Rosiane Nascimento AlvesDepartment of Agricultural and Natural Science, Universidade do Estado de Minas Gerais, Ituiutaba 38302-192, Minas Gerais, Brazil.
Angelica Oliveira GomesLaboratory of Cell Interactions, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, Uberaba 38025-350, Minas Gerais, Brazil.
Ingrid de Oliveira DiasLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (Lab. PARASITTOS), Department of Morphology and Basic Pathology, Faculdade de Medicina de Jundiaí, Jundiaí 13202-550, São Paulo, Brazil.
Juliana Quero ReimãoLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (Lab. PARASITTOS), Department of Morphology and Basic Pathology, Faculdade de Medicina de Jundiaí, Jundiaí 13202-550, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-4418-0838
Bellisa Freitas BarbosaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-4611-2844
Eloisa Amália Vieira FerroLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.
Samuel Cota TeixeiraLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38400-694, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-1978-1658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital toxoplasmosis persists as a significant public health challenge due to the limited efficacy and safety of current treatments during pregnancy. In this study, we assessed the antiparasitic activity and mechanism of action of milciclib (MCB), a cyclin-dependent kinase inhibitor from the Medicines for Malaria Venture Pathogen Box, against

Identifiers

PMID42889618
PMCPMC13670761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.